This paper is marked retracted in the scholarly record (OpenAlex). Interpret its findings with caution.
Retraction Note: Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis
Rui Han, Hongxing Yang, Lingeng Lu, Lizhu Lin
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMarine Sponges and Natural Products · Natural product bioactivities and synthesis · Sesquiterpenes and Asteraceae Studies
Retraction of: Scientific Reports 10.1038/s41598-021-88133-7, published online 21 April 2021
The Editors have retracted this Article. After publication irregularities have been identified in the presented figures, specifically:
- In Figure 2A the 0h Hep3B Tiliroside and NC images overlap;
- Images in Figures 3A and B overlap with images in previously published articles [1, 2].
The Authors provided data files to address these concerns; however, the Editors were unable to validate these files as original data. The Editors therefore no longer have confidence in the reliability of the results presented in this Article.
Hongxing Yang and Lingeng Lu have not responded to correspondence from the Editors about this retraction. Rui Han and Lizhu Lin have not explicitly stated if they agree or disagree with this retraction.